ArticleDigestive diseases and sciences2026
Long-Term Post-transplant Outcomes in Patients with Hepatitis D Virus Infection at a High-Volume Liver Transplant Center.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHepatitis D virus (HDV) infection remains a major cause of liver failure in Türkiye, yet post-transplant outcomes and recurrence predictors are not well defined. This study aimed to evaluate long-term outcomes and risk factors for HDV recurrence following liver transplantation in a high-volume transplant center.
methodsWe retrospectively analyzed 182 patients who underwent liver transplantation for HDV-related liver disease between 2010 and 2024. Clinical, virological, and survival data were compared between patients with and without HDV recurrence. Kaplan-Meier survival and Cox regression analyses were performed to identify independent predictors of recurrence.
resultsHDV recurrence occurred in 12 patients (6.6%) during a median follow-up of 80 months. HBIG administration significantly reduced recurrence risk (HR = 0.001, p < 0.001), while post-transplant HBV recurrence was strongly associated with HDV relapse (p < 0.001). Pre-transplant hepatocellular carcinoma (HCC) showed no significant association with HDV recurrence. Overall survival did not differ significantly between recurrence and non-recurrence groups (p = 0.068).
conclusionsOur results showed that HDV recurrence was infrequent and was not associated with a statistically significant difference in post-transplant survival. Post-transplant HBV recurrence and HBIG therapy were identified as the main factors influencing HDV recurrence. Another important finding was that pre-transplant hepatocellular carcinoma (HCC) was not significantly associated with HDV recurrence. These results provide valuable long-term evidence from an HDV-endemic region and may guide post-transplant management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.